The estimated Net Worth of Alan Charles Foster is at least $24.2 Тысяча dollars as of 25 March 2022. Dr Foster owns over 4,386 units of Otonomy Inc stock worth over $13,630 and over the last 3 years he sold OTIC stock worth over $10,526.
Dr has made over 1 trades of the Otonomy Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 4,386 units of OTIC stock worth $10,526 on 25 March 2022.
The largest trade he's ever made was selling 4,386 units of Otonomy Inc stock on 25 March 2022 worth over $10,526. On average, Dr trades about 2,193 units every 0 days since 2022. As of 25 March 2022 he still owns at least 177,017 units of Otonomy Inc stock.
You can see the complete history of Dr Foster stock trades at the bottom of the page.
Dr. Alan Charles Foster Ph.D. is the Chief Scientific Officer at Otonomy Inc.
Dr D is 65, he's been the Chief Scientific Officer of Otonomy Inc since . There are 1 older and 11 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.
Alan's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.
Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo и Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.
Otonomy Inc executives and other stock owners filed with the SEC include: